AVENIO ctDNA Expanded Kit – Expanded Tumor Profiling

Material Number: N/A

Next-generation sequencing (NGS) liquid biopsy tumor profiling assay for identifying genomic aberrations in solid tumors containing 77 genes.

Technical Datasheet: Technical datasheet

Description

The AVENIO ctDNA Expanded Kit is a next-generation sequencing (NGS) liquid biopsy assay with a 77 gene panel containing genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines2 and emerging cancer biomarkers. The Expanded Kit is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC).

 

Specifications:

  • Panel size: 192 kb
  • Sample size: 4 ml of plasma
  • ctDNA input 10-50 ng
  • Reactions per kit: 16
  • Turn-around time: 5 days from extraction to results

Product Highlight: An accurate detection of all four classes of mutations with high sensitivity and specificity 1 with >99% sensitivity for all four classes of mutations, >99% positive predictive value (PPV) for indels, fusions and CNVs and >98% PPV for SNVs

The present kit includes the following subkits:
For more information or further assistance, please reach out to our local representative through the contact form.

Table demonstrating the performance of AVENIO ctDNA kits

The AVENIO ctDNA Analysis Kits are a portfolio of three NGS liquid biopsy assays for oncology research. These assays provide an end-to-end tumor profiling and longitudinal tumor burden monitoring solution.

2-5._GeneList_4_-_AVENIO_ctDNA_Tumor_Tissue_Expanded_Panel 2-5._GeneList_4_-_AVENIO_ctDNA_Tumor_Tissue_Expanded_Panel 2-5._GeneList_4_-_AVENIO_ctDNA_Tumor_Tissue_Expanded_Panel2-5._GeneList_4_-_AVENIO_ctDNA_Tumor_Tissue_Expanded_Panel

References:

  1. Data on file.
  2. National Comprehensive Cancer Network. October 15, 2016